Objectives: This study to compare prices of Multiple Sclerosis Disease- Modifying Drugs (DMDs) available in Saudi Arabia (SA) vs. that in the United States (US). Methods: This is a cross-sectional study. All prices (in Saudi Riyal [SR]) were collected on the 2nd of January 2016. Prices of DMD per unit in SA were obtained from Saudi Food and Drug Authority (SFDA) website. Average wholesale price (AWP) per unit for DMDs in the US were derived from the RedBook (Truven Health Analytics, Inc.). The defined daily dose (DDD) for adult patients was obtained from DMD labels. Prices per DDD were computed. Descriptive statistics and Wilcoxon test were performed. Statistical significance level was set at 0.05. Results: As of the 2nd of January 2016, there were 7 DMDs (only one oral DMD) in SA while there were 12 DMDs (3 oral DMDs) in the US. The highest DMD price per unit in SA was for natalizumab (SR 4,321.23) while it was for interferon beta-1a (EMD Serono) (SR 1,851.34) in the US. Mitoxantrone hydrochloride has the lowest DMD price per unit in both SA (SR 61.52) and the US (SR 6.87). All DMD prices in SA were lower than that in the US except for two DMDs (natalizumab and mitoxantrone hydrochloride). The median DMD price per unit in SA (median= SR 169.45, IQR= 296.38) was lower than that in the US (median= SR 891.00, IQR= 1025.59) (no statistical significant difference). Conclusions: Most of Saudi DMD prices are lower than the US DMD prices. There was a big difference between the prices of DMDs in both countries. Price control policy adopted by SFDA is one of the contributed factors for lowering the DMD prices in Saudi Market. However, the DMD price difference between SA and the US was not statistically significant.
Bin Sawad, A., & Alkelya, M. (2016). Price Analysis of Multiple Sclerosis Disease-Modifying Drugs: Comparison Between Saudi Arabia and the United States. Value in Health, 19(3), A62. https://doi.org/10.1016/j.jval.2016.03.195